25 related articles for article (PubMed ID: 37078422)
1. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.
Luo M; Yu J; Tang R
J Neurooncol; 2024 May; 167(3):415-425. PubMed ID: 38441839
[TBL] [Abstract][Full Text] [Related]
2. Deficiency in infiltration of CD8/CD3 positive lymphocytes and macrophages plays a role in lip carcinogenesis: an immunohistochemical study.
Magalhães IA; Costa GAJ; Borges MMF; Carlos ACAM; Mesquita KC; Arruda LMA; Cunha MDPSS; Sousa FB; Silva PGB
Braz J Otorhinolaryngol; 2024; 90(2):101379. PubMed ID: 38219446
[TBL] [Abstract][Full Text] [Related]
3. Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.
Serioli S; Agostini L; Pietrantoni A; Valeri F; Costanza F; Chiloiro S; Buffoli B; Piazza A; Poliani PL; Peris-Celda M; Iavarone F; Gaudino S; Gessi M; Schinzari G; Mattogno PP; Giampietro A; De Marinis L; Pontecorvi A; Fontanella MM; Lauretti L; Rindi G; Olivi A; Bianchi A; Doglietto F
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958702
[TBL] [Abstract][Full Text] [Related]
4. Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.
Tapoi DA; Popa ML; Tanase C; Derewicz D; Gheorghișan-Gălățeanu AA
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958474
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.
Ben-Shlomo A; Liu NA; Melmed S
Pituitary; 2017 Feb; 20(1):93-99. PubMed ID: 27900635
[TBL] [Abstract][Full Text] [Related]
6. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours.
Iacovazzo D; Chiloiro S; Carlsen E; Bianchi A; Giampietro A; Tartaglione T; Bima C; Bracaccia ME; Lugli F; Lauretti L; Anile C; Gessi M; Colosimo C; Rindi G; Pontecorvi A; Korbonits M; De Marinis L
Endocrine; 2020 Mar; 67(3):651-658. PubMed ID: 31875303
[TBL] [Abstract][Full Text] [Related]
7. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
[TBL] [Abstract][Full Text] [Related]
8. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
Chiloiro S; Moroni R; Giampietro A; Angelini F; Gessi M; Lauretti L; Mattogno PP; Calandrelli R; Tartaglione T; Carlino A; Gaudino S; Olivi A; Rindi G; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1341-1350. PubMed ID: 37975821
[TBL] [Abstract][Full Text] [Related]
9. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
[TBL] [Abstract][Full Text] [Related]
10. CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs.
Chiloiro S; Giampietro A; Gessi M; Lauretti L; Mattogno PP; Cerroni L; Carlino A; De Alessandris QG; Olivi A; Rindi G; Pontecorvi A; De Marinis L; Doglietto F; Bianchi A
J Neuroendocrinol; 2023 Apr; 35(4):e13263. PubMed ID: 37078422
[TBL] [Abstract][Full Text] [Related]
11. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
